http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022261039-A2
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2cc7b63a63a913d1524a692c352f98be |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-178 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| filingDate | 2022-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22abe9fdc059daa32366e74565b6a4bd http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6d24f942dc7ea53321a395ca9b8ff70c |
| publicationDate | 2022-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022261039-A2 |
| titleOfInvention | Cancer detection method, kit, and system |
| abstract | Provided herein include a method, kit and system capable of detecting one or multiple human cancers with high accuracy. After an expression profile of an miRNA biomarker set comprising one or more miRNAs is determined based on a liquid biopsy sample from a subject, a diagnostic index is calculated, based on which the subject can be classified as having cancer or not. A 4-miRNA biomarker model demonstrates exceptionally high sensitivities of 99.0-100% for lung and gastric cancers, 83.0-99.0% for biliary tract, bladder, colorectal, esophageal, glioma, liver, pancreatic, and prostate cancers, and 68.2-72.0% for ovarian cancer and sarcoma, while maintaining 99.3% specificity. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110799648-A |
| priorityDate | 2021-06-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 588.